Compare Crispr Therapeutics AG (CRSP) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SkyWest Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while SkyWest Inc trades at $97.36 (market cap $3.85B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and SkyWest Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SKYW | |
|---|---|---|
Market Cap | $4.97B | $3.85B |
Sector | Health | Technology |
52-Week High | $76.78 | $123.72 |
52-Week Low | $44.34 | $78.40 |
Enterprise Value | $3.32B | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SkyWest (SKYW) trades at $97.78, down 1.95% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong fundamentals with a P/E of 9.32 and net income margin of 10.42%, supported by recent earnings beats. Analyst consensus is bullish with a $109.33 price target. Recent news includes a key executive appointment and attention to fuel cost pressures in the airline industry.
The outlook for SKYW is positive given its attractive valuation and profitability, but risks include rising fuel expenses and industry volatility. With no sell ratings and 56% buy consensus, the stock presents a compelling opportunity for upside, though investors should monitor cost management and quarterly results closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
